Nanoviricides (NNVC) Other Working Capital Changes (2011 - 2014)
Nanoviricides' (NNVC) quarterly Other Working Capital Changes came in at -$150000.0 in Q3 2014, down 200.0% quarter-over-quarter from $150000.0 in Q2 2014.
Powered by 
Analysis
Nanoviricides (NNVC) Other Working Capital Changes (2011 - 2014) Analysis & Trends
Nanoviricides has disclosed Other Working Capital Changes across 2 years of filings, most recently posting -$150000.0 for Q3 2014.
- In Q3 2014, Other Working Capital Changes changed N/A year-over-year to -$150000.0; the TTM figure through Jun 2015 stood at -$150000.0 (down 200.0% YoY), while the FY2015 annual figure was -$150000.0, down 200.0% from the prior year.
- Other Working Capital Changes came in at -$150000.0 for Q3 2014 at Nanoviricides, down from $150000.0 in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of $150000.0 in Q2 2014 to a low of -$167637.0 in Q2 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Nanoviricides | 22.04 Mn | 18.83 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2014 | -150,000.00 |
| Sep 30, 2014 | -150,000.00 |
| Jun 30, 2014 | 150,000.00 |
| Jun 30, 2014 | 150,000.00 |
| Jun 30, 2011 | -167,637.00 |
| Jun 30, 2011 | -167,637.00 |
| Mar 31, 2011 | -42,265.00 |
| Mar 31, 2011 | -42,265.00 |